27 results
8-K
EX-99.5
KA
Kineta Inc
22 Dec 22
Kineta Completes Reverse Merger with Yumanity Therapeutics
5:02pm
that a financial relationship between Kineta and a principal investigator has created a conflict of interest or otherwise affected interpretation of the trial
424B3
KA
Kineta Inc
10 Nov 22
Prospectus supplement
4:21pm
.
H.C. Wainwright & Co. acted as a financial advisor to both Yumanity and Kineta, which potential conflict of interest could affect its advice to Yumanity … delivered to either or both parties. Upon learning of Kineta’s engagement of Wainwright and the potential conflict of interest created
CORRESP
xmho ykm0h4h1f1
3 Oct 22
Correspondence with SEC
12:00am
UPLOAD
jduyw
26 Sep 22
Letter from SEC
12:00am
8-K
EX-2.7
tib511
6 Jun 22
Yumanity Therapeutics Announces Definitive Agreements for Two Strategic Transactions
4:02pm
8-K
EX-10.6
et1uuc0srg6ucsd
30 Dec 20
Yumanity Therapeutics Completes Reverse Merger with Proteostasis Therapeutics
4:44pm
8-K
EX-10.5
vjfn09sd vgr
30 Dec 20
Yumanity Therapeutics Completes Reverse Merger with Proteostasis Therapeutics
4:44pm
8-K
EX-10.2
u4qqr1s
15 Dec 20
Yumanity Therapeutics to Raise $33.6 Million PIPE Contingent on Completion of Reverse Merger with Proteostasis
7:34am